Valeant bets on anti-aging boom with Medicis takeover bid

September 7, 2012

With 15 acquisition offers this year alone, Valeant Pharmaceuticals International Inc. chief executive J. Michael Pearson looks like a wheeler-dealer in a hurry.

But his latest bet, a $2.6-billion cash bid for U.S.-based Medicis Pharmaceutical Corp., is all about slowing down the effects of time. It’s a gambit to grab a larger share of the anti-aging and dermatology products market. The belief? That spending money to look younger and healthier will only increase in the years ahead.

Click here to read the article.

Share This Story